Forte Biosciences Stock (FBRX) Surges 25% on Positive Celiac Disease Trial Data

Forte Biosciences shares rallied sharply after reporting statistically significant Phase 1b trial results for its celiac disease treatment FB102. The biopharmaceutical company demonstrated a 42% patient benefit during gluten challenge testing, triggering a 23.5% single-day surge that extended Friday's 17.8% gain.

Investors responded enthusiastically to the CD3-positive T cell density improvements and Vh:Cd ratio changes, despite the stock's 35% year-to-date decline prior to the announcement. The company has now advanced to Phase 2 trials, with topline data expected by mid-2026.

Wall Street maintains strong conviction with a unanimous Strong Buy rating and $44.50 price target, suggesting 203% upside potential. The dramatic price movement highlights biotechnology's binary nature—where clinical milestones can rapidly alter valuation trajectories.